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ABSTRACT
Aim: To assess in real life the rate of
hypoglycemia during Ramadan in patients
with type 2 diabetes (T2DM) in France,




study with 2 visits (within 8 weeks before and
6 weeks after the end of Ramadan 2012). Study
diaries were not used to collect events or record
values of glucose monitoring. One hundred and
ninety-eight patients on stable oral dual therapy
for C2 months and with glycosylated
hemoglobin (HbA1c) B8.0% were recruited by
62 centers: 83 in the IS cohort and 115 in the
vildagliptin cohort.
Results: Approximately 90% of patients were
from Maghreb. The two cohorts were well
balanced: 60% men, mean age 59 years, BMI
28 kg/m2, metformin dose *2,000 mg/day, and
HbA1c 7.2%. Distinct therapeutic management
was planned in view of Ramadan with drug-
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adaptation intended in 61.4% of IS and 18.3%
of vildagliptin patients. Hypoglycemia was
reported in 37% of IS and 34% of vildagliptin
patients; episodes declared as confirmed in
30.8% and 23.5%, respectively, and episodes
documented as adverse event (AE) in 17.9% (22
episodes) and 7.5% (13 episodes), respectively
(P = 0.025). Severe episodes were reported in
3.9% of IS and 1.7% of vildagliptin patients.
10.4% of IS and 2.6% of vildagliptin patients
reported severe episodes and/or unscheduled
medical visits due to hypoglycemia (P = 0.029).
Glycemic control remained stable in both
cohorts. Compliance with fasting was high, as
well as adherence to drug with C5 missed-dose
for 15.4% of IS and 8.5% of vildagliptin
patients.
Conclusion: Although the overall frequency of
malaise suggestive of hypoglycemia was high,
which would be expected with prolonged
fasting in a well-controlled T2DM population
during hot summer days, the incidence of more
severe and better-documented episodes (AE,
severe event, event leading to unscheduled
medical visit) were much lower, with
consistently less events with vildagliptin
therapy.
Keywords: Dipeptidyl peptidase-4 inhibitors;
Hypoglycemia; Insulin secretagogues;
Metformin; Ramadan; Type 2 diabetes;
Vildagliptin
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
progressive disease with a worldwide prevalence
that is rapidly increasing. In 2012, more than
371 million people were estimated to have
T2DM [1]. As a result of urbanization and
socioeconomic developments, the prevalence
of diabetes has been rising by 10% annually in
countries with large Muslim populations [2].
Almost a quarter (*1.6 billion) of the world’s
population follows Islam [3, 4]. Although a
majority of them are spread across the Middle
East, North Africa, and parts of Asia, there are
about 4 million Muslims in France [5].
Ramadan is the ninth month of the Islamic
lunar calendar, when healthy Muslims are
obliged to abstain from food and drinks from
sunrise to sunset [6]. Although the Koran [7]
and several guidelines [4, 8, 9] exempt the sick
from fasting, over 50 million Muslims with
diabetes fast during the holy month of
Ramadan each year worldwide [3, 10].
Epidemiologic data from the first large
retrospective study (EPIdemiology of DIAbetes
and Ramadan [EPIDIAR]) conducted in 13
Islamic countries reported that a vast majority
of patients with T2DM (79%) fasted for at least
15 days during Ramadan [11]. The dates of
observance of Ramadan differ each year and
the period of fasting also varies by geographical
location and season, lasting up to 18 h or more
during the summer months in the northern
latitudes [4]. A majority of Muslim patients with
diabetes are ardent about their Ramadan
fasting, despite the potential complications of
fasting, which may include hyperglycemia,
hypoglycemia, and increased risk of
dehydration and thrombosis [10, 12].
Prolonged fasting in the absence of adequate
insulin may lead to excessive glycogen
breakdown and increased gluconeogenesis,
eventually leading to hyperglycemia [4, 10].
On the other hand, the risk of hypoglycemia is
an important factor to be considered when
choosing an antidiabetic agent [10]. This is of
particular concern in the coming decade, as
Ramadan will fall during the summer months,
increasing the number of fasting hours and
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eventually raising the risk of negative effects in
patients with diabetes who wish to fast.
Hypoglycemia is one of the main health risks
during this fasting period [12]. In the EPIDIAR
study, there was a 7.5-fold increase in risk of
severe hypoglycemia leading to hospitalization
during the month of Ramadan as compared
with other months (from 0.4 to 3 events/100
patients/month) in patients with T2DM [11].
The various recommendations for patients with
diabetes who wish to fast include pre-Ramadan
assessments, Ramadan-focused structured
education, and regular blood glucose
monitoring [4, 8, 9, 12, 13].
Sulphonylureas (SUs) and glinides are still
widely used as oral antidiabetic agents during
Ramadan because of their well-established
clinical profiles and low cost [14, 15], but they
are associated with an increased risk of
hypoglycemia, and their use should be
individualized with caution [4]. Highly
variable rates of hypoglycemia have been
reported in published studies with SUs and
glinides [16], ranging from 3% in the
GLImepiride in RAmadan (GLIRA) study [17]
and about 40% in the Vildagliptin Experience
Compared To gliclazide Observed during
Ramadan (VECTOR) study [18]. A recent five-
country, observational study that included
approximately 1,400 patients treated with SUs
during Ramadan reported that the overall
incidence of symptomatic hypoglycemic
events was approximately 20% and the overall
incidence of severe hypoglycemic events was
6.7%, with differences noted across countries
and SUs (glipizide 28%, glibenclamide 26%,
glimepiride 17%, and gliclazide 14%) [19].
Vildagliptin, a dipeptidyl peptidase-4 (DPP-
4) inhibitor, has been shown to be effective and
well tolerated with a low incidence of
hypoglycemia in clinical trials up to 2 years
across disease stages [20], including in higher-
risk populations with more severe consequences
of hypoglycemia, such as in elderly patients
aged C75 years [21], patients with renal
impairment [22], and insulin-treated patients
[23]. The risk of severe hypoglycemia has been
shown to be significantly reduced with
vildagliptin versus SUs [24, 25]. The use of
vildagliptin during Ramadan has also been
recently reported, essentially in Indo-Pakistani
populations from the UK [26] and in cohorts of
UK South Asian Muslim patients (VECTOR
study) [18]. However, little data exist on
populations practicing Ramadan fasting in
France. One such study recently conducted in
Marseille, a crossover point between France and
North Africa with a diverse religious population,
showed the importance of Ramadan fasting for
French Muslim patients and revealed a wide gap
between the patients’ and physicians’ attitudes,
highlighting the need for increased awareness
and more medical training [27].
The present observational study, Vilagliptin
Experience during Ramadan in patients with
DIabetes (VERDI), aimed to evaluate the
management of T2DM in France during
Ramadan 2012 and the rate of hypoglycemia
in patients receiving an ongoing dual therapy of
metformin and vildagliptin or metformin and
SU or glinide. Real-life educational approaches
at the pre-Ramadan visit were collected, such as
adaptation of drug treatment, blood glucose
monitoring, and dietary counseling.
MATERIALS AND METHODS
Study Design
This was a multicenter, prospective,
observational study conducted at 62 centers in
France. General practitioners (GPs) and
diabetologists with experience in managing
T2DM patients wishing to fast during
Diabetes Ther (2013) 4:385–398 387
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Ramadan were invited to take part in the study:
1,649 physicians were contacted, 112 accepted,
and 62 (56 GPs and 6 diabetologists) were active
in recruiting patients between May 18, 2012
and July 18, 2012. Physicians were asked to
include patients attending a routine
consultation within *8 weeks before the start
of Ramadan. Based on the ongoing dual therapy
with either metformin and vildagliptin
(hereafter referred to as the vildagliptin
cohort) or metformin and an insulin
secretagogue (IS) (SU or glinide) (hereafter
referred to as the insulin secretagogue [IS]
cohort), the study population was divided into
two cohorts. The choice of treatments was
independent from the study participation and
all treatments were used in accordance with the
drugs’ prescribing information. The Common
International Names were not collected for the
drugs in the IS cohort. The study was designed
to have 2 visits: the first, or baseline, visit (Visit
1) within 8 weeks before the start of Ramadan
(July 19, 2012) and the follow-up, or final, visit
(Visit 2) within 6 weeks after the end of
Ramadan (August 20, 2012). Prior to Ramadan,
patients could receive specific dietary advice,
and a glucometer could be prescribed for self-
monitoring of blood glucose (SMBG), according
to local practice. Because the study design was
non-interventional, patients received follow-up
as per usual clinical practice without protocol-
mandated intervention. In particular, study
diaries were not requested to record events or
SMBG values. Prior to Ramadan, physicians
could adjust the treatment (dose change and/
or frequency of dosing) within each cohort to
optimally manage their patients.
Patients
Patients included in the study met the
following criteria: C18 years of age, with
T2DM diagnosed at least 12 months prior to
the start of Ramadan and who planned to fast at
least 10 days during Ramadan; receiving dual
therapy of either metformin and an IS (SU or
glinide) or metformin and vildagliptin for at
least 8 weeks before fasting begins, and at least 1
consultation scheduled within 6 weeks after
Ramadan ends; a glycosylated hemoglobin
(HbA1c) level B8.0% approximately 1 month
before the start of Ramadan; and no plans to
spend Ramadan outside of France. Patients with
a history of type 1 diabetes or a secondary form
of diabetes, those requiring C3 oral antidiabetic
therapies or insulin at study entry, and women
who were either pregnant or breast-feeding were
excluded from the study.
Study Assessments
The primary assessment was to evaluate the
incidence of all hypoglycemic episodes during
Ramadan in each of the 2 treatment cohorts.
Hypoglycemic episodes were categorized as
symptomatic; confirmed by self-monitoring
using a glucometer (defined as B70 mg/dL);
severe (defined by the need of a third party);
reported as an adverse events (AE); and
requiring an unscheduled medical visit.
Secondary assessments included the
percentage of patients in each group for whom
therapeutic adaptations were planned prior to
Ramadan and for whom treatment adaptations
were actually made during Ramadan;
percentage of patients in each group in whom
the fast was interrupted; treatment adherence
(number of missed doses and the proportion of
patients who missed C5 doses); and changes
from Visit 1 to Visit 2 in mean HbA1c levels
(with both measurements performed at the
same local laboratory using the Diabetes
Control and Complications Trial reference
method) and body weight. All AEs and serious
388 Diabetes Ther (2013) 4:385–398
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AEs (SAEs) together with their severity and
relationship to the study treatment were
analyzed.
Statistical Analysis
Quantitative or continuous variables were
described by mean and standard deviation
(SD) and in some cases by median and range.
Qualitative variables were described by absolute
frequency and percentage per modality.
Quantitative variables were compared between
groups by student tests in case of normal
distribution and Wilcoxon-Mann–Whitney test
otherwise. Qualitative variables were compared
between groups using the Pearson Chi-squared
test if all theoretical sample sizes were C5 or
using the Fisher test if\5. All tests were adjusted
with a significance level of 5%. If demonstrated,
a statistically significant association between
treatment and hypoglycemic events would not
allow concluding that the treatment is an
independent predictive factor for
hypoglycemic occurrence, since no adjustment
for potential confounding factors was
performed. All statistical analyses were
performed using SAS 9.2 software (SAS
Institute, Cary, NC, USA). Sample size was set
to guarantee sufficient accuracy of the rate of
patients with hypoglycemic events, which is the
main end point of the study.
Ethics
This observational study was conducted in
accordance with the French Privacy Law and
respecting the Recommendations for
professional standards and good
epidemiological practices (ADELF, EPITER,
ADEREST, AEEMA 2007). Candidates for
inclusion were provided with full information
about the study in writing. All data processing
was carried out in compliance with the French
Information Technology and Privacy Law.
RESULTS
Patient Disposition and Baseline
Characteristics
A total of 218 patients (n = 115 for vildagliptin
and n = 83 for IS) were included in the study.
Before the start of the Ramadan fast, 5 patients
from the IS cohort were switched to the
vildagliptin cohort by their physician. All
patients completed the study and 198 were
kept in the final analysis: 120 patients in the
vildagliptin cohort and 78 in the IS cohort. The
remaining 20 patients were excluded from the
study during the follow-up mostly due to
missing or incomplete data and dual therapy
unknown or modified during Ramadan.
Patients were predominantly recruited by GPs
(96%). Over one-third of these active physicians
were practicing across the South of France,
predominantly in Marseille.
The 2 cohorts were well balanced at baseline
(Table 1). About 60% of patients were men; the
mean age was 59.0 years with a mean diabetes
duration of 7.4 years. Mean body mass index
(BMI) was 28.1 kg/m2 with a significant
proportion of obese patients, especially women
(40% of the women and 22% of the men had a
BMI[30 kg/m2). Mean HbA1c level was 7.2% in
both cohorts with 28.7% of patients having an
HbA1c level [7.5%. Approximately 25% of
patients had diabetes-related complications
and 84% had at least 1 associated
cardiovascular risk factor. In line with their
cardiovascular risk profiles, two-thirds of the
patients received concomitant therapies (half
antihypertensive agents, half lipid-lowering,
and approximately one-third antiplatelet
agents). The duration of the dual antidiabetic
Diabetes Ther (2013) 4:385–398 389
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therapy was longer in the IS cohort (3.5 years)
than in the vildagliptin cohort (1.1 year) but the
median total daily dose of metformin was
identical in both (*2,000 mg/day). A majority
of patients in the IS cohort received treatment 3
times a day (66.3%) versus only 29.8% in the
vildagliptin cohort (i.e., additional metformin at
noon). A vast majority of the patients (90.4%)
originated from the Maghreb region (Algeria
*47%, Morocco *28%, and Tunisia *16%).








Age, years (SD) 59.8 (10.3) 58.4 (11.5) 59.0 (11.0)
Age group, years, %
\50 18.1 20.9 19.7
50–\65 48.2 47.0 47.5
65–\75 25.3 26.1 25.8
C75 8.4 6.1 7.1
Gender, male, % 55.4 63.5 60.1
Body weight, kg (SD) 78.4 (12.5) 79.3 (12.4) 78.9 (12.5)
BMI, kg/m2 28.1 (4.8) 28.1 (4.0) 28.1 (4.3)
Men (BMI C 30 kg/m2), % 19.6 23.3 21.8
Women (BMI C 30 kg/m2), % 40.5 40.5 40.5
Region of origin, Maghreb, % 85.5 93.9 90.4
Duration of diabetes, years (SD) 8.1 (6.0) 6.9 (4.4) 7.4 (5.2)
HbA1c, % (SD) 7.2 (0.6) 7.2 (0.6) 7.2 (0.6)
Frequency of daily drug intake, %
Once a day 0.0 0.9* –
Twice a day 33.7 69.3 –
Thrice a day 66.3 29.8 –
Treatment duration, years (SD) 3.5 (3.9) 1.1 (0.8)* –
Metformin, mg
Mean daily dose 2,155 (685) 2,190 (559) –
Median, range 2,100 (850–3,000) 2,000 (700–3,000) –
Diabetes complications, % 22.9 27.0 –
At least 1 microvascular complication 12.0 19.1 –
At least 1 macrovascular complication 18.1 16.5 –
Values are mean (SD) unless indicated otherwise
BMI body mass index, HbA1c glycosylated hemoglobin, IS insulin secretagogue, SD standard deviation
* P\0.001
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Hypoglycemia
Data on all hypoglycemic episodes during
Ramadan, as collected and reported a
posteriori by physicians at the post-Ramadan
visit, are presented in Fig. 1. In all categories of
events, rates of hypoglycemia were numerically
lower in the vildagliptin cohort as compared
with the IS cohort. At least 1 episode of
symptomatic hypoglycemia was reported
during Ramadan in 37.2% of patients in the IS
cohort and 34.2% of patients in the vildagliptin
cohort (P = 0.665). The proportion of patients
in whom at least 1 episode was declared
confirmed by self-testing was 30.8% in the IS
cohort and 23.5% in the vildagliptin cohort
(P = 0.260). More hypoglycemic episodes were
documented by physicians as AEs in the IS
cohort (22 hypoglycemic events reported by
17.9% of patients), compared with the
vildagliptin cohort (13 hypoglycemic events
reported by 7.5% of patients) (P = 0.025). The
proportion of patients reporting at least 1 severe
episode of hypoglycemia that required third-
party assistance was 3.9% in the IS cohort and
1.7% in the vildagliptin cohort (P = 0.392). In
total, 7.7% of patients in the IS cohort resorted
to at least one unscheduled medical visit during
Ramadan because of hypoglycemia as compared
with 1.7% in the vildagliptin cohort
(P = 0.059). Overall, the percentage of patients
with severe hypoglycemia and/or an
unscheduled medical visit due to
hypoglycemia was higher in the IS cohort
than in the vildagliptin cohort (10.4% and
2.6%, respectively, P = 0.029).
Fig. 1 Hypoglycemic events as declared by physicians. AE
adverse event, IS insulin secretagogue. *P = 0.025,
**P = 0.029, ***P = 0.059, ^P = 0.260, $P = 0.392,
#P = 0.665. An AE is the appearance or worsening of any
undesirable sign, symptom, or medical condition occurring
after starting the study drug even if the event is not
considered to be related to study drug. Severe hypoglycemia
means patient unable to initiate self-treatment and requires
assistance of another person or hospitalization. Any
unscheduled visit to a site during the observation period
by patient due to hypoglycemia was considered as unsched-
uled medical visit related to hypoglycemia
Diabetes Ther (2013) 4:385–398 391
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Therapeutic Management
Overall, 95.5% of patients had previously
observed Ramadan fasting while being
diagnosed with T2DM. In terms of therapeutic
management, dietary advice at the pre-
Ramadan visit was provided to a similar
number of patients in both cohorts (*85%).
However, a treatment adaptation, with dose or
frequency adjustment of the treatment, was
planned prior to Ramadan more frequently in
the IS cohort (61.4%) than in the vildagliptin
cohort (18.3%, P\0.001). About three-fourths
of the patients, 80.5% in the IS cohort and
68.4% in the vildagliptin cohort (P = 0.059),
were advised to self-monitor their blood glucose
levels during Ramadan.
Treatment was actually modified for 66.7%
of IS patients and 28.3% of vildagliptin patients
during Ramadan (P\0.001) (Table 2). Among
patients for whom treatment was modified, a
modification of metformin alone was made in
15.4% of patients in the IS and 41.2% of
patients in the vildagliptin cohort, consisting
mostly of dose reduction with suppression of
the mid-day dose. The change predominantly
involved the associated treatment in the IS
cohort (85%) and consisted mostly of a dose
reduction (in 68% of cases) with a change in
timing (suppression of the mid-day dose in 34%






Treatment change, yes, % 66.7* 28.3
Type of treatment change, %
No change 33.3 71.7*
Only metformin change 10.3 11.7
Only associated treatment change 15.4 2.5
Metformin and associated treatment change 41.0 14.2
Treatment adherence








Patients who interrupted fasting C1 day, % 25.6 21.7
IS insulin secretagogue
* P\0.001
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of the cases) and moving the morning dose to
the evening (in 32% of cases).
Adherence to Treatment and Fasting
Overall, approximately 53% of patients adhered
to their treatment during fasting without
interruption. The proportion of patients who
had missed C5 doses was lower in the
vildagliptin cohort (8.5%) than in the IS
(15.4%) cohort, including patients who missed
C5 doses due to hypoglycemia or fear of
hypoglycemia (2.5% and 9.0%, in the
vildagliptin and IS cohorts, respectively)
(Table 2).
Overall, patients fasted on an average for
29.8 days (range 16–31 days). A majority of
patients completed fasting with minimal
interruptions. Temporary diabetes-related
interruptions of the fast for C1 day (mean of
3 days) were reported by 25.6% patients in the
IS group and 21.7% patients in the vildagliptin
group.
Glycemic and Weight Control
Glycemic control remained stable and similar in
both cohorts (from a mean of 7.2% at Visit 1,
mean HbA1c level was 7.2% at Visit 2; 27.7% of
patients had an HbA1c level [7.5%). Body
weight also remained stable in both cohorts
(overall mean at Visit 2 of 78.3 kg: 77.9 kg in the
IS cohort from a mean of 78.4 kg at Visit 1 and
78.6 kg in the vildagliptin cohort from a mean
of 79.3 kg at Visit 1).
Adverse Events
Among the 198 patients, 24 patients had at least
1 AE; a total of 39 AEs were reported. One or
more AEs were reported by 19.2% of patients in
the IS cohort (25 AEs) and 7.5% of patients in
the vildagliptin cohort (14 AEs). The difference
was largely due to the incidence of
hypoglycemia, which was reported as the most
common AE (22 and 13 in the IS and
vildagliptin cohorts, respectively) and were
pre-specified as AEs of clinical relevance in the
study. AEs suspected to be treatment-related
were reported by 10.3% of patients in the IS
cohort and 5.8% in the vildagliptin cohort. No
event led to discontinuation and none were
reported as an SAE. Other AEs, only reported in
the IS cohort, were malaise, dizziness, and
hyperhidrosis, all of which could be related to
hypoglycemic episodes.
DISCUSSION
Despite the Islamic rule of exemption, many
Muslim patients with diabetes choose to fast
during Ramadan [11]. Additionally, fasting has
been associated with a feeling of improvement
in overall well-being, having a positive impact
on social, cultural, and religious domains [28].
Health care professionals are seldom included
in the spiritual decision as to whether or not a
patient chooses to fast during Ramadan [27, 28].
The recent study by Gaborit and colleagues in
France showed that many GPs had limited
medical knowledge of Ramadan fasting in
patients with diabetes, leading to over half of
them proscribing fasting, even when it was not
medically justified. On the other hand, 53% of
patients fasted against medical advice. This
wide gap between GPs’ and patients’ attitudes
highlights the lack of training and subsequent
difficulties in such cross-cultural patient-
physician relationships [27]. However,
structured educational programs, such as the
Ramadan Education and Awareness in Diabetes
(READ) program, have clearly shown positive
effects [28], in particular in minimizing the risk
of hypoglycemia [29, 30]. This Ramadan-
focused diabetes education needs to involve
not just the health care team but also the
patients’ families, friends, community, and
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religious authorities. It empowers patients to
adapt their lifestyle and also helps them take
responsibility for their care beyond the
Ramadan fast [29, 31, 32]. In addition to these
educational programs, newer pharmacologic
agents with a reduced risk of hypoglycemia,
such as DDP-4 inhibitors, may be a safer option
for patients with diabetes during fasting [4, 11].
In view of that consideration, the current
prospective, real-life study primarily aimed to
compare the incidences of hypoglycemia during
Ramadan fasting between patients with T2DM
treated with stable dual oral therapy of
metformin and vildagliptin or metformin and
IS. This observational study is one of the first to
evaluate the therapeutic management of
Ramadan fasting in French Muslim patients
with well-controlled T2DM. It showed that all
categories of hypoglycemic events were
numerically lower in the vildagliptin cohort
compared with the IS cohort. Overall, the
frequency of malaise suggestive of
hypoglycemia was relatively high in both
cohorts, reported in about one-third of
patients with a small between-group
difference. This could be attributed to the
prolonged fasting hours of over 18 h a day
during hot summer days, making it difficult to
ascertain the hypoglycemic nature of all malaise
events. However, the overall frequency of
better-documented hypoglycemic episodes
and/or more severe events (hypoglycemic
events reported as AEs, hypoglycemia
requiring unscheduled medical visit, and
severe episodes requiring third-party
assistance) was lower in both cohorts, with
consistently fewer events with vildagliptin
therapy compared with traditional insulin
secretors (SU or glinide). This finding is in line
with recent observations and experience with
vildagliptin during Ramadan in other
populations and regions of the world. In a UK
retrospective audit conducted in North West
London with Muslim patients of mostly
Pakistani and Middle Eastern origins,
confirmed hypoglycemic events (defined as
blood glucose \3.5 mmol/L with or without
symptoms) were recorded during Ramadan in 2
(7.7%) patients receiving vildagliptin and 16
(61.5%) patients receiving gliclazide [25].
Similarly, in a UK observational study of South
Asian patients, VECTOR, none of the 23
patients treated with vildagliptin as add-on to
metformin reported hypoglycemia during
Ramadan, in contrast to the 15 (41.7%)
patients receiving SU therapy [17]. In the
much larger VIldagliptin expeRience compared
wiTh sulfonylUrea obsErved during Ramadan
(VIRTUE) study enrolling Muslim patients from
10 countries in the Middle East and Asia,
significantly fewer patients experienced
hypoglycemia with vildagliptin (n = 684)
(5.4%) compared with SU (n = 631) (19.8%)
(P\0.001) [33]. These findings are similar to
the incidence observed for the hypoglycemic
events reported as AEs in the present (VERDI)
study (7.5% and 17.9% with vildagliptin and IS,
respectively), a smaller study limited to a
population originating mostly from the
Maghreb region. Patients enrolled in the
VERDI study had well-controlled T2DM (mean
HbA1c level of 7.2%), and glycemic control did
not deteriorate over the short follow-up period
in either treatment groups. This is also
consistent with findings from VIRTUE, in
which the mean HbA1c level was 7.3% and
7.4% in the vildagliptin and SU cohorts,
respectively, and changed by -0.24% in the
vildagliptin group and ?0.02% in the SU group
over the course of the study.
Overall, treatment adherence was high in the
VERDI study, as only 8.5% of vildagliptin-
treated patients and 15.4% of IS-treated
patients omitted their treatment C5 times
394 Diabetes Ther (2013) 4:385–398
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during Ramadan. High treatment adherence
with vildagliptin during Ramadan has recently
been shown to be better than that reported with
SU in the VECTOR study [34]. Treatment
adherence was also high overall in the VIRTUE
study, but with a similar number of missed
doses between cohorts [33]. Besides, compliance
to fasting was important in the present study,
with patients fasting on average for 29.8 days.
Only about one-fourth of patients (21.7% on
vildagliptin and 25.6% on IS) reported a
temporary diabetes-related interruption of
fasting for C1 day. Conversely, daily
consumption of sweets is often increased
during Ramadan with iftar, the main meal
breaking the fast, being a festive time, but
information on total daily food/sugar intake
was not collected in the study.
Finally, in the VERDI study, GPs seemed to
plan less therapeutic adjustments and
treatment modifications for vildagliptin-
treated patients during Ramadan, which
suggests that physicians are more at ease when
prescribing DPP-4 inhibitors in this context of
fasting. This is not surprising, in view of the low
propensity of DPP-4 inhibitors to cause
hypoglycemia.
DPP-4 inhibitors can be considered as an
alternative to SUs for vulnerable patients at
high risk for hypoglycemia [3, 20]. For instance,
the use of DPP-4 inhibitors in the elderly in real-
life practice was associated with a lower
incidence of hypoglycemic events (6.4%)
versus SU or glinides (26%) over 6 months
despite a similar improvement in glucose
control [35]. Convincing data have started to
accumulate for the use of DPP-4 inhibitors in
other situations that increase the risk of
hypoglycemia such as prolonged fasting
during Ramadan [18, 26, 36, 37]. In addition
to the data already described with vildagliptin,
studies with sitagliptin have been published. In
a large, open-label trial in T2DM patients from
India and Malaysia, patients were randomized
to either remain on their pre-study SU regimen
or to switch to sitagliptin 100 mg. Of a total 848
patients, 3.8% of sitagliptin-treated patients
(n = 421) and 7.3% of the SU-treated patients
(n = 427) recorded C1 hypoglycemic events
during Ramadan [37]. Similarly, in another
open-label, randomized study, 1,021 patients
from the Middle East were either switched to
sitagliptin or remained on their pre-study SU
regimen, and 6.7% of the patients in the
sitagliptin group compared with 13.2% in the
SU group recorded C1 event of symptomatic
hypoglycemia [36].
The current study has several limitations.
The main one was that the collection of
hypoglycemic ‘‘malaises’’ was not subjected to
mandatory recording on a daily study diary or
to systematic supervision. Patients’ answers
may have had a memory bias, and except for
the events that were documented as AEs, the
reporting of hypoglycemic episodes was mostly
based on recollection. The exact quantification
of hypoglycemia remained a hard task because
‘‘various’’ malaises during the long fasting
period (*18 h) over hot summer days may
have interfered with the data. Because this
non-interventional study aimed at examining
real-life practices, SMBG was not requested. In
addition, information about the type of SUs
used in the study was not collected; however, in
France the most widely prescribed SU is
gliclazide. Another limitation was that the
study had a relatively small sample size and
included only French Muslim patients, mostly
from the Maghreb region, who were relatively
recently diagnosed and had well-controlled
T2DM with dual oral therapy. Therefore,
results cannot be necessarily extended to the
Diabetes Ther (2013) 4:385–398 395
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general Muslim population, who may be using
more complex treatment and have more
advanced disease.
CONCLUSION
Nevertheless, despite the limitations of the
observational methodology, the results were
consistent, particularly regarding the data that
were better documented (hypoglycemic events
reported as AEs, severe episodes, and
hypoglycemia leading to unscheduled medical
visit) and showed numerically lower frequencies
of hypoglycemia with vildagliptin as compared
with traditional insulin secretors. In this well-
controlled T2DM population fasting for over
18 h/day during hot summer days, GPs planned
fewer therapeutic adjustments for vildagliptin-
treated patients compared with IS-treated
patients prior to Ramadan, suggesting a greater
ease with dosing regimens for DPP-4 inhibitors
in situations where the risk of hypoglycemia is
increased. Given the increasing importance of
how best to treat patients with T2DM during
Ramadan coupled with the paucity of
information available in France, especially
from real-life practice, these observations
represent a valuable contribution to the
existing evidence to help physicians choose
between oral antidiabetic drug classes.
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